I-Mab Biopharma to split US, China businesses to cut costs, mitigate potential risks
I-Mab Biopharma may have long taken pride in being a China-based global player, but from here on out, it wants to be known as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
